Sobi Proposes Former Ericsson CEO Börje Ekholm As New Board Chair

Swedish Orphan Biovitrum has proposed Börje Ekholm as a new Board member and Chair of the Board, with shareholders expected to consider the nomination at Sobi’s 2027 Annual General Meeting.

The proposed appointment follows current Chair David Meek’s decision not to seek re-election.

Meek has served as a member and Chair of Sobi’s Board since December 2024 and is expected to remain in the position through the end of his current term in May 2027.

Sobi credited Meek’s tenure with supporting strong company growth and shareholder returns, expanded access to medicines through new product launches and indication extensions, and continued development of the company’s clinical pipeline.

Ekholm brings more than three decades of experience spanning technology, investment management, international business, and board leadership.

He recently stepped down as Chief Executive Officer of Ericsson.

Earlier in his career, Ekholm served as CEO of Patricia Industries and Investor AB.

He currently serves as Chair of Trimble and has been appointed to the Board of Nasdaq effective November 1, 2026.

His previous board appointments include Alibaba, Husqvarna, Nasdaq, Scania, and WM Data.

Ekholm also serves as a board advisor to Mars and an advisor to Ericsson’s CEO.

During his tenure leading Investor, Ekholm was involved in the creation of Sobi through the merger of Biovitrum and Swedish Orphan International and worked with the company from an ownership perspective.

Sobi employs approximately 2,000 people across Europe, North America, the Middle East, Asia, and Australia and reported SEK 28 billion in revenue in 2025.

KEY QUOTES:

“We are pleased to propose Börje Ekholm as the new Chair of the Sobi Board.”

“Börje has significant global leadership and board experience and is very familiar with the company.”

Daniel Nodhäll, Chair Of The Sobi Nomination Committee